Literature DB >> 16466032

Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review.

A Fraser1, M Paul, A Attamna, L Leibovici.   

Abstract

SETTING: The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin, is a threat to global TB control.
OBJECTIVE: To appraise evidence of the effectiveness of treatment of latent TB infection (LTBI) in people at risk for developing active MDR-TB.
DESIGN: Systematic review of comparative studies of people treated and not treated for LTBI following exposure to MDR-TB. DATA SOURCES: PubMed, EMBASE, LILACS and the Cochrane Library (December 2004).
RESULTS: Two observational studies met inclusion criteria. A prospective cohort study found individualised tailored treatment to be effective for preventing active TB in children (OR = 0.20, 95%CI 0.04-0.94), while a retrospective cohort study found INH not to be effective (OR = 0.46, 95%CI 0.07-2.32).
CONCLUSION: Evidence of the effects of treatment of LTBI in people exposed to MDR-TB is extremely limited in both quantity and quality. The increasing global spread of MDR-TB and the difficulties in treating it emphasise the need for effective preventive measures. Ideally, this issue should be addressed in a randomised controlled trial. Until such a trial is conducted, routine clinical data collected as part of existing TB control programmes could be useful and can be generated relatively easily.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466032

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  13 in total

Review 1.  Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis.

Authors:  A Fraser; M Paul; A Attamna; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  A relook at preventive therapy for tuberculosis in children.

Authors:  Varinder Singh; Soumya Patra
Journal:  Indian J Pediatr       Date:  2010-10-27       Impact factor: 1.967

3.  Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.

Authors:  Sundari R Mase; John A Jereb; Daniel Gonzalez; Fatma Martin; Charles L Daley; Dorina Fred; Ann M Loeffler; Lakshmy R Menon; Sapna Bamrah Morris; Richard Brostrom; Terence Chorba; Charles A Peloquin
Journal:  Pediatr Infect Dis J       Date:  2016-04       Impact factor: 2.129

4.  Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.

Authors:  Nishi Suryavanshi; Matthew Murrill; Amita Gupta; Michael Hughes; Anneke Hesseling; Soyeon Kim; Linda Naini; Lynne Jones; Betsy Smith; Nikhil Gupte; Rodney Dawson; Vidya Mave; Sushant Meshram; Alberto Mendoza-Ticona; Jorge Sanchez; Nagalingeswaran Kumarasamy; Kyla Comins; Francesca Conradie; Justin Shenje; Sandy Nerette Fontain; Anthony Garcia-Prats; Aida Asmelash; Supalert Nedsuwan; Lerato Mohapi; Umesh Lalloo; Ana Cristina Garcia Ferreira; Elisha Okeyo; Susan Swindells; Gavin Churchyard; N Sarita Shah
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

Review 5.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

6.  Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study.

Authors:  Patrick K Moonan; Larry D Teeter; Katya Salcedo; Smita Ghosh; Shama D Ahuja; Jennifer Flood; Edward A Graviss
Journal:  Lancet Infect Dis       Date:  2013-06-05       Impact factor: 25.071

Review 7.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

8.  The use of anti-tuberculosis therapy for latent TB infection.

Authors:  Justin T Denholm; Emma S McBryde
Journal:  Infect Drug Resist       Date:  2010-07-21       Impact factor: 4.003

9.  Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses.

Authors:  Ioana Nicolau; Daphne Ling; Lulu Tian; Christian Lienhardt; Madhukar Pai
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting.

Authors:  James Johnston; Andrew Admon; Amir Ibrahim; Kevin Elwood; Patrick Tang; Victoria Cook; Mark Fitzgerald
Journal:  BMC Infect Dis       Date:  2012-10-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.